Skip to main content
CAPR
NASDAQ Life Sciences

Capricor Q3 Loss Widens to $42.7M; Cash Falls to $198.5M Ahead of Nov 22 PDUFA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.35
Mkt Cap
$515.693M
52W Low
$2.96
52W High
$40.37
52W Position info
216% above low
Off High info
77% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CAPR has more than doubled off its 52-week low of $2.96.

Summary

Capricor's Q3 net loss widened to $42.7 million and cash plus securities fell to $198.5 million from $318.1 million at year-end. The quarter also brought a 10% workforce cut in September and disclosure of a new Mesoblast patent suit. Management says the balance funds at least twelve months of operations.


Key Events · Earnings and Guidance · CAPR

  • Q3 Loss Widens to $42.7M

    Net loss was $42.7 million ($0.73 per share) versus $24.6 million ($0.54) a year earlier, and the nine-month loss reached $117.3 million versus $74.9 million.

  • Cash Falls to $198.5M

    Cash, restricted cash and marketable securities totaled $198.5 million at September 30, 2026, down from $318.1 million at December 31, 2025; management says this funds at least twelve months of operations.

  • Expenses Jump on Launch Prep

    Q3 R&D rose 45% to $29.6 million and G&A rose 155% to $15.1 million, driven by manufacturing scale-up, commercial readiness and legal costs.

  • 10% Workforce Reduction

    A September 2026 reduction affected about 10% of employees, with $579,000 of one-time termination benefits recorded.


Analysis · CAPR · Life Sciences

Cash burn is the number that matters this quarter: $198.5 million remained at September 30 versus $318.1 million at year-end, set against a $117.3 million nine-month net loss and a quarterly loss that widened to $42.7 million from $24.6 million. Spending is running ahead of the story, with R&D up 45% and G&A up 155% as Capricor staffs up for a launch that has not been approved. Management states the balance funds operations for at least the next twelve months, yet the company also took a 10% workforce reduction in September, which reads as cost discipline ahead of the November 22, 2026 PDUFA date. Meanwhile the legal stack keeps growing: a new Mesoblast patent suit plus additional securities class actions naming the CEO and CFO.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CAPR was trading at $9.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $515.7M. The 52-week trading range was $2.96 to $40.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CAPR - Latest Insights

CAPR
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.10
Real-time Price: $9.40 info
Change: +$0.300 (+3%) info
Market Cap: $515.693M info
CAPR
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.91
Real-time Price: $9.40 info
Change: +$0.495 (+6%) info
Market Cap: $515.693M info
CAPR
Nov 09, 2026, 9:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.08
Real-time Price: $9.40 info
Change: +$0.317 (+3%) info
Market Cap: $515.693M info
CAPR
Oct 05, 2026, 12:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $8.22
Real-time Price: $9.40 info
Change: +$1.18 (+14%) info
Market Cap: $515.693M info
CAPR
Sep 29, 2026, 9:24 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $10.27
Real-time Price: $9.40 info
Change: -$0.870 (-8%) info
Market Cap: $515.693M info